All In Biotech

Drug Trial Radar · NCT06775340

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Jan 22, 2025

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis

Conditions

  • Adolescent Asthma

Interventions

  • RSS0343 TabellaDrug

    RSS0343 tablets, oral;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of occurrences of AEsTime frame: Day 1 to Day56
  2. the frequency of occurrence of AEsTime frame: Day 1 to Day56

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.